论文部分内容阅读
目的 :通过免疫调节剂日达仙联合化疗药物经动脉介入栓塞化疗治疗恶性肿瘤 ,观察其安全性、有效性、可行性。方法 :5 8例肝癌、胃癌、肺癌患者分二组 ,A组日达仙 +化疗药物经动脉介入栓塞治疗 ,B组单纯化疗药物经动脉介入栓塞治疗。结果 :日达仙 +化疗药物组介入后副作用明显低于单纯化疗药物组 ,而且细胞免疫水平无明显下降 ,NK细胞及CD4 /CD8比例略有升高。结论 :日达仙联合化疗药物经动脉介入栓塞化疗是安全有效和可行的 ,值得进一步观察应用
OBJECTIVE: To observe the safety, efficacy and feasibility of the treatment of malignant tumors by the interventional chemoembolization and chemotherapeutic drugs by the adjuvant immunosuppressant Zadaxin. Methods: Fifty-eight patients with hepatocellular carcinoma, gastric cancer and lung cancer were divided into two groups. Group A was treated with arterial embolization of Zadaxian and chemotherapy drugs. Group B chemotherapy alone was treated with arterial embolization. Results: The side effects of Zadaxin + chemotherapeutic drug group were significantly lower than that of chemotherapy alone group, but no significant decrease in cellular immunity, NK cells and CD4 / CD8 ratio increased slightly. Conclusion: Zadaxin combined with chemotherapy drugs by arterial embolization chemotherapy is safe and effective and feasible, it is worth further observation and application